{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-022191","form_type":"8-K","ticker":"DNA","cik":"0001830214","company_name":"Ginkgo Bioworks Holdings, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.505174+00:00","generated_at":"2026-06-02T06:57:03.973760+00:00","sec_items":["2.02","2.05","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Ginkgo Bioworks Q1 revenue $38M (-53% YoY), plans $200M cost cuts, targets EBITDA breakeven by end 2026","bullets":["Q1 total revenue $38M, down 53% YoY; Cell Engineering $28M (-18%), Biosecurity $10M.","Loss from operations $178M (incl. $42M SBC); Adj. EBITDA -$100M, flat YoY; cash $840M, no debt.","Restructuring: reduce annualized opex by $200M by mid-2025, cut labor >=25%, consolidate facilities up to 60%.","Targeting adjusted EBITDA breakeven by end-2026; 2024 revenue guidance lowered to $170-190M.","Added 17 new Cell Programs in Q1; expects at least 100 new customer projects in 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-022191","json":"https://secwatch.observer/filing/0001628280-24-022191.json","markdown":"https://secwatch.observer/filing/0001628280-24-022191.md","text":"https://secwatch.observer/filing/0001628280-24-022191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024022191/0001628280-24-022191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024022191/dna-20240509.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T06:57:03.973760+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d7c6e11c5b9c729258a6a808a0aa7805b9eb11c","claim":"Ginkgo Bioworks Holdings, Inc. reported first quarter ended March 31, 2024 results: revenue $38 million.","evidence_excerpt":"First quarter 2024 Total revenue of $38 million, down from $81 million in the comparable prior year period","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1830214/000162828024022191/0001628280-24-022191-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Revenue","value":"$38 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}